Article
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 Protein Vaccine
2022-12-06
Abstract excerpt
<h4>Background</h4> COVID-19 vaccines with alternative strain compositions are needed to provide broad protection against newly emergent SARS-CoV-2 variants of concern. <h4>Methods</h4> We conducted a global Phase 3, multi-stage efficacy study ( NCT04904549 ) among adults aged ≥18 years. Participants were randomized 1:1 to receive two intramuscular injections 21 days apart of a bivalent SARS-CoV-2 recombinant p...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 3369b36e-df5b-5c26-af0a-ad1778ef524e
- DOI
- 10.1101/2022.12.05.22282933
